r 56865 has been researched along with lidoflazine in 1 studies
| Studies (r 56865) | Trials (r 56865) | Recent Studies (post-2010) (r 56865) | Studies (lidoflazine) | Trials (lidoflazine) | Recent Studies (post-2010) (lidoflazine) |
|---|---|---|---|---|---|
| 72 | 1 | 0 | 229 | 37 | 14 |
| Protein | Taxonomy | r 56865 (IC50) | lidoflazine (IC50) |
|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.0159 | |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | 4.954 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borgers, M; De Clerck, F; Vandewiele, R; Ver Donck, L; Verellen, G | 1 |
1 other study(ies) available for r 56865 and lidoflazine
| Article | Year |
|---|---|
Class IV Ca2+ antagonists do not affect lipid peroxidation in singlet oxygen challenged cardiomyocytes.
Topics: Animals; Benzothiazoles; Calcium Channel Blockers; Cell Separation; Cinnarizine; Diltiazem; Flunarizine; Lidoflazine; Lipid Peroxidation; Malondialdehyde; Myocardium; Nicardipine; Oxygen; Piperidines; Rats; Thiazoles; Verapamil | 1990 |